A clinical approach to the threat of emerging influenza viruses in the <scp>A</scp>sia‐<scp>P</scp>acific region

Hui, David S.; Lee, Nelson; Chan, Paul K.S.

doi:10.1111/resp.13114

Cited by 27 publications

(26 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also effective against subtypes of T-20-resistant HIV mutants and primary HIV-2 isolates. A further assay from the same group led to the improvement of 2P23 which, by adding a fatty acid group (C 16 ) to its C terminus, produced LP-19 [16]. The results showed that LP-19 could inhibit HIV-1, -2 and SIV in much lower concentrations than 2P23, especially in the assay for inhibition of virus entry.…”

Section: Human Immunodeficiency Virusmentioning

confidence: 99%

“…The influenza virus presents a major threat to human health as it has been responsible for many epidemics over the years [16]. Given their segmented single-stranded RNA genome, influenza viruses have a high degree of genomic variation, which is caused by point mutation changes or large sequence reassortment [153], triggered when an animal is infected by different strains of influenza that can exchange genome segments, thus resulting in a new strain [154].…”

Section: Influenza Virus Inspired Peptidesmentioning

confidence: 99%

“…Because of its specificity-it requires a phosphorylation step mediated by a viral protein-this molecule causes lower toxicity for the host when compared with previously used treatments [10,11]. Unfortunately, the low efficacy of antiviral treatments is still evidenced by the ever-increasing reports of viral resistance [12][13][14], concomitant viral infections [15], and the emergence and re-emergence of viral epidemics in relatively short periods of time, as observed for H1N1, Ebola and zika virus (ZIKV) only in the first 5 years of the present decade [16][17][18][19][20]. Therefore, the demand for production of new antiviral drugs is higher than ever, with increased preference for molecules capable of presenting broad-spectrum activity [21].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antiviral peptides as promising therapeutic drugs

Boas

Campos

Berlanda

et al. 2019

Cell. Mol. Life Sci.

242

175

View full text Add to dashboard Cite

While scientific advances have led to large-scale production and widespread distribution of vaccines and antiviral drugs, viruses still remain a major cause of human diseases today. The ever-increasing reports of viral resistance and the emergence and re-emergence of viral epidemics pressure the health and scientific community to constantly find novel molecules with antiviral potential. This search involves numerous different approaches, and the use of antimicrobial peptides has presented itself as an interesting alternative. Even though the number of antimicrobial peptides with antiviral activity is still low, they already show immense potential to become pharmaceutically available antiviral drugs. Such peptides can originate from natural sources, such as those isolated from mammals and from animal venoms, or from artificial sources, when bioinformatics tools are used. This review aims to shed some light on antimicrobial peptides with antiviral activities against human viruses and update the data about the already well-known peptides that are still undergoing studies, emphasizing the most promising ones that may become medicines for clinical use.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Section: Human Immunodeficiency Virusmentioning

confidence: 99%

Section: Influenza Virus Inspired Peptidesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antiviral peptides as promising therapeutic drugs

Boas

Campos

Berlanda

et al. 2019

Cell. Mol. Life Sci.

242

175

View full text Add to dashboard Cite

show abstract

“…Following the influenza A (H1N1) pandemic in 2009, seasonal influenza remains a critical public health issue (1). Besides neuraminidase inhibitor treatment, influenza pneumonia often requires hospitalization and antibiotic therapy for a possible bacterial coinfection (2).…”

Section: Introductionmentioning

confidence: 99%

Clinical features of Mycoplasma pneumoniae coinfection and need for its testing in influenza pneumonia patients

Kim¹,

Kwon²,

Lee³

et al. 2018

J. Thorac. Dis

View full text Add to dashboard Cite

Background: To investigate the clinical features of coinfection due to Mycoplasma pneumoniae (M. pneumoniae), a common copathogen in influenza, in influenza pneumonia patients. Methods: We reviewed 4,465 patients with influenza who visited a tertiary care hospital emergency department in Seoul (Korea) from 2010 through 2016, and underwent immunoglobulin M (IgM) serology or polymerase chain reaction (PCR) for M. pneumoniae. Influenza pneumonia was defined as laboratoryconfirmed influenza plus radiographic pneumonia. Patients with healthcare-associated pneumonia or non-mycoplasma bacterial coinfection were excluded. Clinical, laboratory, and radiographic findings and outcomes of the influenza pneumonia patients with and without M. pneumoniae coinfection were compared.Multivariable logistic regression analysis was performed to identify factors associated with the coinfection. Results: Of 244 influenza pneumonia patients, 41 (16.8%) had M. pneumoniae coinfection. These patients were younger with a higher frequency of age of 5-10 years, and had higher white blood cell (WBC) and lymphocyte counts; lower concentration of C-reactive protein (CRP). The coinfection had no association with specific radiographic findings and poor outcome. Multivariable analysis showed the age of 5-10 years (adjusted odds ratio, 18.83; 95% confidence interval, 5.899-60.08; P<0.001) as the factor associated with the coinfection. Conclusions: M. pneumoniae coinfection in influenza pneumonia may be associated with the age of 5-10 years, and otherwise clinically indistinct from influenza pneumonia without the coinfection. This finding suggests the need for M. pneumoniae testing in patients aged 5-10 years with influenza pneumonia.

show abstract

“…The 2009 H1N1 pandemic virus disproportionately affected children and young adults. Patients with chronic co-morbid illness, and those at the extremes of age and pregnant women are at higher risks of complications requiring hospitalization [3]. The 2009 H1N1 pandemic virus spread was so rapid that with 168 countries reported infections by mid-2009 [4] with more than 162,000 laboratory-confirmed cases and over a thousand human deaths [5].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2018

Bioinformation

View full text Add to dashboard Cite

Influenza viruses A and B are important human respiratory pathogens causing seasonal, endemic and pandemic infections in several parts of the globe with high morbidity and considerable mortality. The current inactivated and live attenuated vaccines are not effective. Therefore, it is of interest to design universal influenza virus vaccines with high efficacy. The peptide GQSVVSVKLAGNSSL of pandemic influenza, the peptide DKTSVTLAGNSSLCS of seasonal influenza and the peptide DILLKFSPTEITAPT of influenza B were identified as potential linear cell mediated epitopes. The epitopes predicted by BepiPred (B-cell epitope designer) program was subjected to docking experiment-using HexDock and CABS dock programs. The epitopes of pandemic H1N1 influenza A gave similar score of high affinity in docking. The epitope DKTSVTLAGNSSLCS of seasonal influenza A and epitope DILLKFSPTEITAPT of influenza B had high binding energy. It is further observed that the peptides GQSVVSVKLAGNSSL (pandemic influenza), DKTSVTLAGNSSLCS (seasonal influenza) DILLKFSPTEITAPT (influenza B) are found to interact with some known MHC class II alleles. These peptides have high-affinity binding with known MHC class II alleles. Thus, they have the potential to elicit cell immune response. These vaccines have to be further evaluated in animal models and human volunteers. These findings have application in the development of peptide B-cell epitope vaccines against influenza viruses.

show abstract

A clinical approach to the threat of emerging influenza viruses in the Asia‐Pacific region

Cited by 27 publications

References 98 publications

Antiviral peptides as promising therapeutic drugs

Antiviral peptides as promising therapeutic drugs

Clinical features of Mycoplasma pneumoniae coinfection and need for its testing in influenza pneumonia patients

Untitled

Contact Info

Product

Resources

About